NCT01159769View on ClinicalTrials.gov

Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis

PHASE4CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Allergic Conjunctivitis
Interventions
DRUG

Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)

Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY